CP Pharmaceuticals Ltd. Sustainability Profile
CP Pharmaceuticals Ltd., headquartered in Great Britain, is a prominent player in the pharmaceutical industry, specialising in the development and manufacturing of high-quality generic and specialty medicines. Founded in the early 2000s, the company has established a strong presence in key operational regions across Europe and beyond. With a diverse portfolio that includes injectable products, oral solid dosage forms, and advanced drug delivery systems, CP Pharmaceuticals is recognised for its commitment to quality and innovation. The company’s unique approach to product development and stringent quality control measures have positioned it as a trusted partner in the healthcare sector. Notable achievements include securing multiple regulatory approvals and expanding its market reach, solidifying CP Pharmaceuticals Ltd. as a leader in the pharmaceutical landscape.
DitchCarbon Score
How does CP Pharmaceuticals Ltd.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
CP Pharmaceuticals Ltd.'s score of 28 is higher than 52% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
CP Pharmaceuticals Ltd., headquartered in Great Britain, currently does not have specific carbon emissions data available for the most recent year. The company is a current subsidiary of Wockhardt Limited, and any emissions data would be inherited from this parent organization. As of now, CP Pharmaceuticals Ltd. has not set specific reduction targets or made climate pledges that are publicly documented. The absence of detailed emissions data and reduction initiatives suggests that the company may still be in the early stages of formalising its climate commitments. In the context of the pharmaceutical industry, many companies are increasingly focusing on sustainability and carbon reduction strategies. CP Pharmaceuticals Ltd. may benefit from aligning with industry standards and initiatives to enhance its environmental performance in the future.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2024 | |
|---|---|
| Scope 1 | 1,801,110 |
| Scope 2 | - |
| Scope 3 | 24,596,930 |
How Carbon Intensive is CP Pharmaceuticals Ltd.'s Industry?
How Carbon Intensive is CP Pharmaceuticals Ltd.'s Location?
CP Pharmaceuticals Ltd.'s Scope 3 Categories Breakdown
Their carbon footprint includes supplier sustainability and value chain emissions data across Scope 3 categories, with "Downstream Transportation & Distribution" being the largest emissions source at 45% of Scope 3 emissions.
Top Scope 3 Categories
CP Pharmaceuticals Ltd.'s Climate Goals (2030 & 2050)
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
CP Pharmaceuticals Ltd. has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
Let us know if this data was useful to you
Usage Policy
You're welcome to quote or reference data from this page, but please include a visible link back to this URL.
Bulk collection, resale, or redistribution of data from multiple profiles is not permitted.
See our License Agreement for more details.